Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

Shares of Profusa (PFSA) hit a record low on Thursday, crashing 28% after the biotech company announced its second reverse ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large ...

It might pull it off, provided several things fall right in place.

Parabilis Medicines is ambitious, but it has Regeneron on its side already.

Against that backdrop, Seeking Alpha's Quant Ratings highlight a number of biotechnology companies that currently rank among ...